COVID-19 in cystic fibrosis patients

Кондратьева, Е. И.; Krasovskiy, S.; Kashirskaya, N.; Zhekayte, E.; Sherman, V.; Simonova, O.; Gorinova, Y.; Бойцова, Е В; Mukhina, M. A.; Makarova, M. A.; Malakhov, A. B.

doi:10.18093/0869-0189-2020-30-5-544-552

Cited by 4 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, it is possible that some lung-transplanted pwCF no longer participate in ECFSPR and the number of infections in pwCF living with a transplant could be under-reported here. Of note, pwCF from 11 countries in our study were also included in the global study [7] and in national or center-based studies [ 5 , 19 , 21 , 32 ] in pwCF.…”

Section: Discussionmentioning

confidence: 99%

Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020

Naehrlich

Orenti

Dunlevy³

et al. 2021

Journal of Cystic Fibrosis

View full text Add to dashboard Cite

Background Viral infections can cause significant morbidity in cystic fibrosis (CF). The current Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic could therefore have a serious impact on the health of people with CF (pwCF). Methods We used the 38-country European Cystic Fibrosis Society Patient Registry (ECFSPR) to collect case data about pwCF and SARS-CoV-2 infection. Results Up to 30 June 2020, 16 countries reported 130 SARS-CoV-2 cases in people with CF, yielding an incidence of 2.70/1000 pwCF. Incidence was higher in lung-transplanted patients (n=23) versus non-transplanted patients (n=107) (8.43 versus 2.36 cases/1000). Incidence was higher in pwCF versus the age-matched general population in the age groups <15, 15-24, and 25-49 years (p<0.001), with similar trends for pwCF with and without lung transplant. Compared to the general population, pwCF (regardless of transplantation status) had significantly higher rates of admission to hospital for all age groups with available data, and higher rates of intensive care, although not statistically significant. Most pwCF recovered (96.2%), however 5 died, of whom 3 were lung transplant recipients. The case fatality rate for pwCF (3.85%, 95% CI: 1.26-8.75) was non-significantly lower than that of the general population (7.46%; p=0.133). Conclusions SARS-CoV-2 infection can result in severe illness and death for pwCF, even for younger patients and especially for lung transplant recipients. PwCF should continue to shield from infection and should be prioritized for vaccination.

show abstract

Section: Discussionmentioning

confidence: 99%

Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020

Naehrlich

Orenti

Dunlevy³

et al. 2021

Journal of Cystic Fibrosis

View full text Add to dashboard Cite

show abstract

“…В Российской Федерации среди пациентов с муковисцидозом (МВ) заболеваемость COVID-19 на 01.08.2020 составила 3,8 (0,38 %) на 1 тыс. пациентов (2,1 : 1000 -для детей и 8,8 : 1000 -для взрослых) [2]. Несмотря на то что пациенты с МВ находятся в группе риска тяжелого течения заболевания COVID-19, инфекция не привела к значительному ухудшению их состояния по основному заболеванию.…”

unclassified

“…Несмотря на то что пациенты с МВ находятся в группе риска тяжелого течения заболевания COVID-19, инфекция не привела к значительному ухудшению их состояния по основному заболеванию. У российских пациентов с МВ не зарегистрировано ни одного летального исхода от COVID-19 [2]. Среди взрослых больных МВ, проживающих в Санкт-Петербурге и Ленинградской области, заболеваемость COVID-19 составила 17,85 % -меньше, чем в общей популяции.…”

unclassified

“…4 / Pediatrician (St. Petersburg). 2022;13(4) eiSSN 2587-6252 оБЗоРы / rEViEwS 79 тить, что среди факторов риска тяжелого течения COVID-19 у больных МВ отсутствует пожилой возраст, потребление табака, особенно активное табакокурение [2,25]. Нельзя исключить и роль самоизоляции в случае такого тяжелого заболевания, как МВ.…”

unclassified

See 1 more Smart Citation

Chronic obstructive lung diseases as a risk factor for severe COVID-19 (review)

et al. 2022

View full text Add to dashboard Cite

The review presents meta-analyses and original studies data of severe outcomes of COVID-19 infection in patients with chronic obstructive pulmonary disease. The main risk factors for the severe course of COVID-19 in many studies have been identified as follows: age over 65 years, chronic lung diseases, systemic arterial hypertension, cardiovascular diseases, diabetes mellitus, immunosuppression, chronic kidney and liver diseases. It was shown that patients with concomitant respiratory diseases were 4.2 times more likely to have a severe course of COVID-19 (OR 4.21; 95% CI 2.96.0), especially in patients with chronic obstructive pulmonary disease (OR 5.8, 95% CI 3.98.5). Patients with bronchial asthma also more often received mechanical ventilation (OR 1.58; 95% CI 1.022.44; p = 0.04), treatment in intensive care units (OR 1.58; 95% CI 1.092.29; p = 0.02), had longer hospital stays (OR 1.30; 95% CI 1.091.55; р 0.003) and higher mortality (OR 1.53; 95 % CI 1.012.33; p = 0.04) compared with COVID-19 patients without asthma or other chronic obstructive pulmonary diseases. Another factor contributing to severe outcomes of COVID-19 is tobacco use, which increases the risk of severe disease, hospitalization and poor outcomes. Patients with chronic obstructive pulmonary diseases, especially smokers, were more likely to have a severe COVID-19 and adverse outcomes of this disease, which must be taken into account when prescribing treatment for coronavirus infection.

show abstract

Analysis of COVID-19 cases in adult cystic fibrosis patients in Saint-Petersburg and the Leningrad region

Makhmutova¹,

Gembitskaya

Chermenskiy

et al. 2021

Pulʹmonologiâ (Mosk.)

View full text Add to dashboard Cite

March 11, 2020 WHO has declared the COVID-19 coronavirus pandemic. The European Society for Cystic Fibrosis (ECFS) has developed the ECFSCOVID- 19 surveillance program to collect information on the characteristics of COVID-19 in patients with cystic fibrosis (CF). CF centers in the Russian Federation also joined the ECFS study. The ECFS collected information only through national Registers. In our country, the national register of CF patients has existed since 2011, its data is included in the European Register. Тo analyze the prevalence and course of COVID-19 in adult CF patients in Saint-Petersburg and the Leningrad region.Methods. From 11.03.20 to 24.12.20, 10 cases of adult CF patients (4 women, 6 men) with COVID-19 were analyzed in Saint-Petersburg and the Leningrad region. At the beginning of the study, 56 adult CF patients lived in Saint-Petersburg and Leningrad Region. All patients were monitored remotely by telephone, in case of ARVI symptoms, disease exacerbation, a PCR smear was performed on SARS-CoV-2, therapy was prescribed remotely, and inpatient treatment was prescribed if indicated.Results. COVID-19 was diagnosed in 10 adult CF patients aged 21 to 43 years. Two patients (32-year-old male and 31-year-old female with severe mixed cystic fibrosis form) were hospitalized with polysegmental pneumonia. 8 people were treated on an outpatient basis. Only 1 outpatient patient aged 43 years had pronounced clinical manifestations of COVID-19, the condition was regarded as moderate, the remaining outpatient patients suffered from a mild ARI disease. All patients were treated with positive dynamics. During the period of this follow – up, 3 CF patients (2 men, 1 woman) died, the death cause was the respiratory failure progression. Clinical and radiological, repeated laboratory data for COVID-19 were not obtained. At the point of December 24, 2020 53 adult CF patients are alive.Conclusion. According to our data, the incidence of COVID-19 among adult CF patients in Saint-Petersburg and the Leningrad Region was 17.85%, which is a lower indicator than in the general population. The disease was rarely severe, and effective treatment was noted in outpatient settings. There were no deaths from COVID-19.

show abstract

COVID-19 in cystic fibrosis patients

Cited by 4 publications

References 6 publications

Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020

Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020

Chronic obstructive lung diseases as a risk factor for severe COVID-19 (review)

Analysis of COVID-19 cases in adult cystic fibrosis patients in Saint-Petersburg and the Leningrad region

Contact Info

Product

Resources

About